National centralized insulin collection starts today in Guangxi

Original title: The national centralized procurement of insulin will be launched in Guangxi today, with an average price reduction of 48% and a maximum price reduction of 73%

The reporter learned from the Autonomous Region Medical Insurance Bureau that from May 30, the medical and health institutions in our region will uniformly implement the results of the sixth batch of nationally organized centralized drug procurement (special insulin) results
.
This insulin centralized procurement is the first time that the centralized drug procurement organized by the state has expanded from chemical drugs to biological drugs, and it is an important milestone in the process of centralized procurement reform
.

Insulin is an important drug for the treatment of diabetes, with a large number of patients and long-term use
.
The results of this centralized procurement have a high level of homogeneity, which is highly matched with the actual clinical needs, covering a total of 16 generic varieties of second-generation and third-generation insulin commonly used in clinical practice.
Including well-known enterprise products commonly used by medical institutions, as well as emerging enterprise products, are mature products that have been market and clinically proven
.

After the results of this selection are implemented, it is estimated that the annual cost savings of 105 million yuan will be calculated based on the procurement volume of about 3.
64 million pieces reported by the medical and health institutions in the region in the first year
.
Taking insulin glargine, which is commonly used in clinical practice, as an example, the average cost of treatment has been reduced from 180 yuan per vial to about 70 yuan per vial before centralized collection, and each diabetic patient can save about 4,000 yuan in treatment costs per year
.
(Reporter Luo Qi correspondent Long Yixin Jiang Yanfei)